These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25443499)

  • 21. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
    Patel M; Hoffe S; Malafa M; Hodul P; Klapman J; Centeno B; Kim J; Helm J; Valone T; Springett G
    J Surg Oncol; 2011 Aug; 104(2):155-61. PubMed ID: 21520097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
    Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of borderline resectable pancreatic adenocarcinoma.
    Jia Y; Wang TJ; Allendorf J; Saif MW
    JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
    Gerber N; Ilson DH; Wu AJ; Janjigian YY; Kelsen DP; Zheng J; Zhang Z; Bains MS; Rizk N; Rusch VW; Goodman KA
    Dis Esophagus; 2014 Apr; 27(3):235-41. PubMed ID: 23796070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.
    Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L
    Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for borderline-resectable pancreatic cancer.
    Okamura Y; Nishitai R; Sasaki N; Ito H; Sakamoto T; Itokawa Y; Kusumoto M; Nakai Y; Yamaoka T; Manaka D
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):546-554. PubMed ID: 38771310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
    Tzeng CW; Fleming JB; Lee JE; Xiao L; Pisters PW; Vauthey JN; Abdalla EK; Wolff RA; Varadhachary GR; Fogelman DR; Crane CH; Balachandran A; Katz MH
    Ann Surg Oncol; 2012 Jun; 19(6):2045-53. PubMed ID: 22258816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer.
    Miura JT; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Oshima K; Christians KK; Evans DB; Tsai S
    Surgery; 2015 Dec; 158(6):1545-55. PubMed ID: 26243342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.
    Stessin AM; Meyer JE; Sherr DL
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1128-33. PubMed ID: 18538501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
    J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
    Itchins M; Arena J; Nahm CB; Rabindran J; Kim S; Gibbs E; Bergamin S; Chua TC; Gill AJ; Maher R; Diakos C; Wong M; Mittal A; Hruby G; Kneebone A; Pavlakis N; Samra J; Clarke S
    Eur J Surg Oncol; 2017 Sep; 43(9):1711-1717. PubMed ID: 28688722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.
    Katz MH; Varadhachary GR; Fleming JB; Wolff RA; Lee JE; Pisters PW; Vauthey JN; Abdalla EK; Sun CC; Wang H; Crane CH; Lee JH; Tamm EP; Abbruzzese JL; Evans DB
    Ann Surg Oncol; 2010 Jul; 17(7):1794-801. PubMed ID: 20162463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
    Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.